Endoscopic advances in the treatment of dysplastic Barrett oesophagus — should HALO be canonised or do we need more evidence?

Chatura S Jayasekera, Finlay A Macrae, Paul V Desmond and Andrew C F Taylor
Med J Aust 2011; 194 (5): . || doi: 10.5694/j.1326-5377.2011.tb02948.x
Published online: 7 March 2011

New ablative techniques can eradicate dysplastic Barrett oesophagus more effectively, but require longer-term follow-up to strengthen their evidence base

Barrett oesophagus is a precursor lesion that can progress to oesophageal adenocarcinoma. Barrett oesophagus affects about 1% of the population and is believed to be due to chronic gastro-oesophageal reflux disease.1 Patients with Barrett oesophagus have a 30–40-fold relative risk of developing oesophageal adenocarcinoma, which usually occurs via progression through low-grade dysplasia (LGD) to high-grade dysplasia (HGD).2

  • Chatura S Jayasekera1
  • Finlay A Macrae2,3
  • Paul V Desmond1
  • Andrew C F Taylor1

  • 1 St Vincent’s Hospital, Melbourne, VIC.
  • 2 Royal Melbourne Hospital, Melbourne, VIC.
  • 3 Department of Medicine, University of Melbourne, Melbourne, VIC.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.